Delphine Collin

Delphine Collin is a seasoned professional in drug discovery and biophysical chemistry, currently serving as SVP and Head of Drug Discovery at Sonata Therapeutics since January 2024. Prior experience includes roles as VP Head of the condensate platform and External Innovation at Faze Medicines, where an integrated platform was created for small molecule and target discovery, and VP of Biomolecular Sciences at Cedilla Therapeutics. Delphine also held the Chief Innovation Officer position at HarkerBIO, contributing to advancements in drug discovery through structural biology. Earlier experiences encompass significant roles at Boehringer Ingelheim as Senior Principal Scientist in small molecule lead discovery and as Biophysics Team Leader at Merck, focusing on small molecule screening techniques. Delphine's academic background includes a PhD in Biophysical Chemistry and a PharmD from Paris-Sud University.